Ankylosing spondylitis and axial spondyloarthritis

New England Journal of Medicine

Volumn 374, Issue 26, 2016, Pages 2563-2574

  Taurog, Joel D ^a   Chhabra, Avneesh ^a   Colbert, Robert A ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; AXIAL SPONDYLARTHRITIS; AXIAL SPONDYLOARTHRITIS; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; GENETIC ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SACROILIITIS; SEX RATIO; SPINE RADIOGRAPHY; SPONDYLARTHRITIS; THORAX PAIN; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES; ALGORITHM; ANTAGONISTS AND INHIBITORS; BACK PAIN; COMPLICATION; DIFFERENTIAL DIAGNOSIS; PATHOLOGY; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; SPINE; SPONDYLITIS, ANKYLOSING;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACK PAIN; CHRONIC PAIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY; SPINE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84976477013     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1406182     Document Type: Review

References (76)

1. Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a crosssectional survey. Arthritis Care Res (Hoboken) 2012; 64:905-10.
2. van Hoeven L, Luime J, Han H, Vergouwe Y, Weel A. Identifying axial spondyloarthritis in Dutch primary care patients, ages 20-45 years, with chronic low back pain. Arthritis Care Res (Hoboken) 2014; 66:446-53.
3. Bywaters E. Historical introduction. In: Moll J, ed. Ankylosing spondylitis. Edinburgh: Churchill-Livingstone, 1980:1-15.
4. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361-8.
5. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68:777-83.
6. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of Spondylo Arthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31.
7. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61-6.
8. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009; 68:784-8.
9. van den Berg R, de Hooge M, Rudwaleit M, et al. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Ann Rheum Dis 2013; 72:1646-53.
10. Wendling D, Prati C, Demattei C, Loeuille D, Richette P, Dougados M. Anterior chest wall pain in recent inflammatory back pain suggestive of spondyloarthritis. data from the DESIR cohort. J Rheumatol 2013; 40:1148-52.
11. Feldtkeller E, Rudwaleit M, Zeidler H. Easy probability estimation of the diagnosis of early axial spondyloarthritis by summing up scores. Rheumatology (Oxford) 2013; 52:1648-50.
12. Wang R, Gabriel SE, Ward MM. Progression of patients with non-radiographic axial spondyloarthritis to ankylosing spondylitis: a population-based cohort study. Arthritis Rheumatol 2016; 68:1415-21.
13. Sieper J, van der Heijde D. Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum 2013; 65:543-51.
14. Wallis D, Haroon N, Ayearst R, Carty A, Inman RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol 2013; 40: 2038-41.
15. Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis 2013; 72:162-4.
16. van der Linden S, Akkoc N, Brown MA, Robinson PC, Khan MA. The ASAS criteria for axial spondyloarthritis: strengths, weaknesses, and proposals for a way forward. Curr Rheumatol Rep 2015; 17: 62.
17. Colbert RA Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond. Nat Rev Rheumatol 2010; 6:477-85.
18. Weiss PF, Xiao R, Biko DM, Chauvin NA. Assessment of sacroiliitis at diagnosis of juvenile spondyloarthritis by radiography, magnetic resonance imaging, and clinical examination. Arthritis Care Res (Hoboken) 2016; 68:187-94.
19. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009; 68: 1520-7.
20. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68:Suppl 2:ii1-44.
21. Weber U, Østergaard M, Lambert RG, et al. Candidate lesion-based criteria for defining a positive sacroiliac joint MRI in two cohorts of patients with axial spondyloarthritis. Ann Rheum Dis 2015; 74: 1976-82.
22. Larbi A, Viala P, Molinari N, et al. Assessment of MRI abnormalities of the sacroiliac joints and their ability to predict axial spondyloarthritis: a retrospective pilot study on 110 patients. Skeletal Radiol 2014; 43:351-8.
23. Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2015 October 13 (Epub ahead of print).
24. Song IH, Hermann KG, Haibel H, et al. Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis-3-year data of the ESTHER trial. Semin Arthritis Rheum 2016; 45: 404-10.
25. Pedersen SJ, Maksymowych WP. Recent advances in imaging of the axial skeleton in spondyloarthritis for diagnosis, assessment of treatment effect, and prognostication. Curr Rheumatol Rep 2015; 17: 60.
26. Soker G, Bozkirli ED, Soker E, et al. Magnetic resonance imaging evaluation of shoulder joint in patients with early stage of ankylosing spondylitis: a casecontrol study. Diagn Interv Imaging 2016; 97: 419-24.
27. Zhao YH, Li SL, Liu ZY, et al. Detection of active sacroiliitis with ankylosing spondylitis through intravoxel incoherent motion diffusion-weighted MR imaging. Eur Radiol 2015; 25:2754-63.
28. Kennedy LG Disease and outcome indices/instruments for the spondylopathies. In: Calin A, Taurog JD, eds. The spondyolarthritides. Oxford, United Kingdom: Oxford University Press, 1998: 239-50.
29. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64:127-9.
30. Fernández-Espartero C, de Miguel E, Loza E, et al. Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis 2014; 73:1350-5.
31. Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/ axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol 2012; 24:363-9.
32. Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69:1465-70.
33. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor a inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65:2645-54.
34. Vander Cruyssen B, Vastesaeger N, Collantes-Estévez E. Hip disease in ankylosing spondylitis. Curr Opin Rheumatol 2013; 25:448-54.
35. Gladman DD What is peripheral spondyloarthritis? Arthritis Rheumatol 2015; 67:865-8.
36. Rosenbaum JT Uveitis in spondyloar thritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol 2015; 34: 999-1002.
37. Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inf lammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013; 72:414-7.
38. Davey-Ranasinghe N, Deodhar A. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2013; 25:509-16.
39. Akgöl G, Kamanli A, Ozgocmen S. Evidence for inflammation-induced bone loss in non-radiographic axial spondyloarthritis. Rheumatology (Oxford) 2014; 53:497-501.
40. McGonagle D, Thomas RC, Schett G. Spondyloarthritis: may the force be with you? Ann Rheum Dis 2014; 73: 321-3.
41. Smith JA, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol 2014; 66:231-41.
42. Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol 2014; 26:361-70.
43. Venken K, Elewaut D. IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear. Curr Rheumatol Rep 2015; 17:30.
44. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012; 18:10 69-76.
45. Poddubnyy D, Sieper J. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. Curr Opin Rheumatol 2014; 26: 377-83.
46. Khan MA Polymorphism of HLA-B27: 105 subtypes currently known. Curr Rheumatol Rep 2013; 15:362.
47. Galocha B, de Castro JA Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis. Arthritis Rheum 2008; 58:401-12.
48. Jeanty C, Sourisce A, Noteuil A, et al. HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloar thritis. Arthritis Rheumatol 2014; 66: 2113-23.
49. ∗27 subtypes associated with ankylosing spondylitis. Arthritis Rheumatol 2016; 68:1172-82.
50. Cortes A, Pulit SL, Leo PJ, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun 2015; 6:7146.
51. Bowness P. HLA-B27. Annu Rev Immunol 2015; 33:29-48.
52. Gill T, Asquith M, Rosenbaum JT, Colbert RA. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol 2015; 27:319-25.
53. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009; 60:2633-43.
54. Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011; 186:2672-80.
55. Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, Lories RJ, Baeten DL. Animal models as a tool to dissect pivotal pathways driving spondyloarthritis. Arthritis Rheumatol 2015; 67:2813-27.
56. Talpin A, Costantino F, Bonilla N, et al. Monocyte-derived dendritic cells from HLA-B27+ axial spondyloarthritis (SpA) patients display altered functional capacity and deregulated gene expression. Arthritis Res Ther 2014; 16: 417.
57. Fert I, Cagnard N, Glatigny S, et al. Reverse interferon signature is characteristic of antigen-presenting cells in human and rat spondyloarthritis. Arthritis Rheumatol 2014; 66:841-51.
58. Fert I, Glatigny S, Poulain C, et al. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/HUMAN β2-micro-globulin-transgenic rat lines. Arthritis Rheum 2008; 58:3425-9.
59. Araujo LM, Fert I, Jouhault Q, et al. Increased production of interleukin-17 over interleukin-10 by treg cells implicates inducible costimulator molecule in experimental spondyloarthritis. Arthritis Rheumatol 2014; 66:2412-22.
60. Stoll ML, Kumar R, Morrow CD, et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther 2014; 16: 486.
61. Lin P, Bach M, Asquith M, et al. HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. PLoS One 2014; 9(8):e105684.
62. Reveille JD Genetics of spondyloarthritis - beyond the MHC. Nat Rev Rheumatol 2012; 8:296-304.
63. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14: 661-73.
64. Uddin M, Codner D, Hasan SM, Scherer SW, O'Rielly DD, Rahman P. Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways. Sci Rep 2015; 5:10314.
65. Coffre M, Roumier M, Rybczynska M, et al. Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis. Arthritis Rheum 2013; 65:1510-21.
66. Tran TM, Colbert RA. Endoplasmic reticulum aminopeptidase 1 and rheumatic disease: functional variation. Curr Opin Rheumatol 2015; 27:357-63.
67. Appel H, Maier R, Loddenkemper C, et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol 2010; 37: 823-8.
68. Tan S, Wang R, Ward MM. Syndesmophyte growth in ankylosing spondylitis. Curr Opin Rheumatol 2015; 27: 326-32.
69. Braun J, van den Berg R, Baraliakos X, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896-904.
70. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2016; 68:282-98.
71. Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. II. specific management recommendations. J Rheumatol 2015; 42: 665-81.
72. Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNFa blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2015; 74: 1 241-8.
73. Deodhar A, Reveille JD, van den Bosch F, et al. The concept of axial spondyloarthritis: joint statement of the Spondyloarthritis Research and Treatment Network and the Assessment of Spondylo Arthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol 2014; 66:2649-56.
74. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465-82.
75. Boulman N, Rimar D, Rozenbaum M, Slobodin G, Younis S, Rosner I. Antitumor necrosis factor treatment and pregnancy: the way is open. Clin Exp Rheumatol 2012; 30: 453.
76. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015; 373:2534-48.